4D Molecular Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
4D Molecular Therapeutics has a total shareholder equity of $600.6M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $629.9M and $29.3M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
Interest coverage ratio | n/a |
Cash | US$525.91m |
Equity | US$600.56m |
Total liabilities | US$29.32m |
Total assets | US$629.88m |
Recent financial health updates
We're Not Very Worried About 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Rate
Nov 08Here's Why We're Watching 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Situation
May 08We're Keeping An Eye On 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Rate
Sep 29Here's Why We're Watching 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Situation
Jun 11We're Hopeful That 4D Molecular Therapeutics (NASDAQ:FDMT) Will Use Its Cash Wisely
Aug 06We Think 4D Molecular Therapeutics (NASDAQ:FDMT) Can Afford To Drive Business Growth
May 04Recent updates
4D Molecular Therapeutics: Catalysts With Pioneering Gene Therapy With Directed Evolution
Apr 294D Molecular Therapeutics Advances Wet AMD Treatment Paradigm
Feb 064D Molecular Therapeutics: Several Value Inflection Points To Watch In 2024
Jan 254D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Just Reported And Analysts Have Been Cutting Their Estimates
Nov 12We're Not Very Worried About 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Rate
Nov 08Here's Why We're Watching 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Situation
May 08We're Keeping An Eye On 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Rate
Sep 294D Molecular Therapeutics GAAP EPS of -$0.87, revenue of $0.16M
Aug 11Here's Why We're Watching 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Situation
Jun 11We're Hopeful That 4D Molecular Therapeutics (NASDAQ:FDMT) Will Use Its Cash Wisely
Aug 06Newsflash: 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Analysts Have Been Trimming Their Revenue Forecasts
Jun 284D Molecular inks collaboration deal on machine learning technology
May 04We Think 4D Molecular Therapeutics (NASDAQ:FDMT) Can Afford To Drive Business Growth
May 04Have Insiders Been Buying 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Shares?
Mar 11Financial Position Analysis
Short Term Liabilities: FDMT's short term assets ($535.6M) exceed its short term liabilities ($16.4M).
Long Term Liabilities: FDMT's short term assets ($535.6M) exceed its long term liabilities ($12.9M).
Debt to Equity History and Analysis
Debt Level: FDMT is debt free.
Reducing Debt: FDMT has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: FDMT has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: FDMT has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 23.4% each year